Amneal Pharmaceuticals (AMRX) Net Income towards Common Stockholders (2018 - 2026)

Amneal Pharmaceuticals' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at $78.0 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 216.84% year-over-year to $78.0 million; the TTM figure through Mar 2026 stood at $181.3 million (up 459.27% YoY), while the FY2025 annual figure was $127.9 million, up 209.45% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $78.0 million, up from $49.6 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $78.0 million in Q1 2026, with the low at -$120.8 million in Q2 2022.
• The 5-year median for Net Income towards Common Stockholders is $9.7 million (2023), against an average of -$4.8 million.
• Peak annual rise in Net Income towards Common Stockholders reached 460.06% in 2023, while the deepest fall reached 2176.69% in 2023.
• Amneal Pharmaceuticals' Net Income towards Common Stockholders stood at -$4.3 million in 2022, then plunged by 2176.69% to -$98.6 million in 2023, then soared by 78.97% to -$20.7 million in 2024, then surged by 339.0% to $49.6 million in 2025, then surged by 57.34% to $78.0 million in 2026.
• Business Quant data shows AMRX's Net Income towards Common Stockholders at $78.0 million in Q1 2026, $49.6 million in Q4 2025, and $18.1 million in Q3 2025.